Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran.
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Pediatr Allergy Immunol. 2017 Aug;28(5):478-484. doi: 10.1111/pai.12735. Epub 2017 Jun 19.
LPS-responsive beige-like anchor protein (LRBA) deficiency is a combined immunodeficiency caused by mutation in LRBA gene. The patients have a variety of clinical symptoms including hypogammaglobulinemia, recurrent infections, autoimmunity, and enteropathy.
A total of 17 LRBA-deficient patients were enrolled in this longitudinal study. For all patients, demographic information, clinical records, laboratory, and molecular data were collected.
Hypogammaglobulinemia was reported in 14 (82.4%), CD4 T-cell deficiency in five (29.4%), NK cell deficiency in three (21.4%), and CD19 B-cell deficiency in 11 (64.7%) patients. All patients had history of infectious complications; pneumonia was the most common (76.5%) occurring infection. A history of lymphoproliferative disorders was observed in 14 (82.3%), enteropathy in 13 (76.5%), allergic symptoms in six (35.5%), neurologic problems in four (23.5), and autoimmunity (mostly autoimmune cytopenia) in 13 (76.5%) patients. Sirolimus treatment improved enteropathy of patients with remarkable success. The 20-year overall survival rate declined to 70.6%.
LRBA deficiency has a very broad and variable phenotype and should be considered, especially in children with early-onset hypogammaglobulinemia, severe autoimmune manifestations, enteropathy, lymphoproliferation, and recurrent respiratory tract infections.
脂多糖反应性米色样锚蛋白(LRBA)缺陷是一种由 LRBA 基因突变引起的联合免疫缺陷。患者有多种临床表现,包括低丙种球蛋白血症、反复感染、自身免疫和肠病。
本纵向研究共纳入 17 例 LRBA 缺陷患者。所有患者均采集人口统计学信息、临床记录、实验室和分子数据。
14 例(82.4%)患者存在低丙种球蛋白血症,5 例(29.4%)患者存在 CD4 T 细胞缺陷,3 例(21.4%)患者存在 NK 细胞缺陷,11 例(64.7%)患者存在 CD19 B 细胞缺陷。所有患者均有感染并发症史;肺炎最常见(76.5%)。14 例(82.3%)患者有淋巴组织增生性疾病史,13 例(76.5%)患者有肠病史,6 例(35.5%)患者有过敏症状,4 例(23.5%)患者有神经问题,13 例(76.5%)患者有自身免疫(主要为自身免疫性血细胞减少症)。西罗莫司治疗显著改善了患者的肠病。20 年总生存率下降至 70.6%。
LRBA 缺陷具有非常广泛和多变的表型,应予以考虑,尤其是在有早发性低丙种球蛋白血症、严重自身免疫表现、肠病、淋巴组织增生和反复呼吸道感染的儿童中。